Bli medlem
Bli medlem

Du är här


Batavia Biosciences: Batavia Biosciences - A new name, in keeping with a recognised market position

Leiden, the Netherlands, April 24 2015

Batavia Bioservices announces its decision to change its name to Batavia
Biosciences as of April 23, 2015. The change will coincide with the launch of
a new website and multimedia communication strategy.

Since its establishment in 2009, the company has experienced rapid growth and
has established itself as a globally recognised and reliable partner for
biotech companies, large pharmaceutical companies, government agencies, and

Batavia Biosciences is recognized for the added value that the company brings
to its partnerships, utilizing in-depth knowledge of developing and
manufacturing complex biopharmaceuticals, including recombinant proteins,
antibodies, vaccines and vectors. The unique technologies the company
possesses including STEPTM and SCOUTTM also facilitate accelerated product
development at reduced cost and a significant increase in the success of an
ultimate product launch.

"Our new name, Batavia Biosciences, better reflects the added value and
scientific support that our company brings to our partners as well as our R&D
staff's efforts in developing exciting novel technologies to accelerate
biopharmaceutical product development", commented Menzo Havenga, CEO. "Our
highly educated and experienced R&D staff is well recognised for their
intellectual input in solving challenges early on in the process of
developing novel or biosimilar biopharmaceuticals", added Chris Yallop, COO.

Vincent Franssen Commercial Director, Europe&Asia: "The name change is in
keeping with a new and clear positioning of Batavia Biosciences' scientific
contribution to our customers biotechnology projects". A multimedia
communication strategy will be rolled out over the coming months. We
encourage you to visit our new

About Batavia Biosciences

Batavia Biosciences ( aims to significantly contribute to ease human
suffering from disease by
improving the success rate in the translation of candidate medicines from
discovery to the clinic. We offer our novel technologies and in depth know
how in order to help our sponsors to complete their preclinical phases in
biopharmaceutical product development at higher speed, reduced cost and
increased success. The company focuses on the early stages of product
development including mammalian cell line generation, upstream process
development (mammalian&microbial), purification development, product
characterization and clinical manufacturing. Headquartered in Leiden, The
Netherlands, with a US-based facility in Woburn, Massachusetts, and offices
in Hong Kong, Batavia Biosciences is privileged to have strong strategic
partners worldwide. For more information you can contact Vincent Franssen,
Commercial Director.

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Batavia Biosciences via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.